Close Menu

J&J

Johnson & Johnson Development Corporation was among the investors in the company's $22 million Series C financing round.

The company will use its lead discovery service to study compounds for J&JPRD.

Instead of focusing on whole-genome sequencing, which they all said was still too expensive, the three pharma companies are focusing on either specific genes, a portion of the exome, or the transcriptome.

SpeeDx, a spinout of Johnson & Johnson's Australian research subsidiary, claims its multi-component nucleic acid enzymes, or MNAzymes, provide significant advantages over current enzymes for multiplex qPCR applications.

The World Wide Web Consortium's Health Care and Life Sciences Interest Group is plotting a semantic course to help find ways for pharma to communicate across drug discovery and development phases.

Pairings: Jan 6, 2010

Premium

Eric Nelson; Call for Nominations for Dr. Paul Janssen Award

The Dutch array vendor is working closely with partners in the pharmaceutical industry and academia to optimize internally developed kinase-screening assays for use in drug discovery and as companion diagnostics.

Under the CRADA, Ortho Biotech, a unit of J&J's Centocor, will have an option to exclusively license new inventions developed jointly or independently by NCI scientists. The collaboration will focus on engineering patients' T-cells to treat melanoma and possibly other types of cancers.

BioArray Briefs: 2009.04.07

Premium

CGC Genetics, Nuvera Biosciences, Veridex, ImaGenes, CapitalBio, Fisher Healthcare, Osmetech, National Institutes of Health, Clinical Data, Cogenics, UK Biotechnology and Biological Sciences Research Council

The assays that Veridex will commercialize were developed to predict patient response to tamoxifen therapy and taxane-containing chemotherapy in breast cancer.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.